[Renal Damage and Obesity: a Silent Pairing]

G Ital Nefrol. 2023 Jun 29;40(3):2023-vol3.
[Article in Italian]

Abstract

Obesity is recognized as a true chronic disease and an independent risk factor for kidney disease. In particular, a correlation was observed between obesity and the development of focal segmental glomerulosclerosis. The clinical consequences of obesity on the kidney can include albuminuria, nephrotic syndrome, nephrolithiasis, and increased risk of development and progression of renal failure. Conventional therapy, which includes low-calorie diet, exercise, lifestyle changes, and drug therapy, including GLP1-RA, phentermine, phentermine/topiramate, bupropion/naltrexone, orlistat, is not always able to achieve the desired results and above all does not guarantee stabilization of body weight over time. On the other hand, bariatric surgery is giving excellent results in terms of efficacy and duration. Bariatric surgery techniques that are generally divided into restrictive, malabsorptive, and mixed are not free from possible metabolic complications such as anemia, vitamin deficiency, and stones. However, they are able to ensure a good maintenance of weight loss obtained with disappearance or reduction of the incidence and severity of comorbidities related to obesity.

Keywords: bariatric surgery; obesity; renal failure; sleeve gastrectomy.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Anti-Obesity Agents* / therapeutic use
  • Humans
  • Kidney
  • Obesity / complications
  • Orlistat / therapeutic use
  • Phentermine / adverse effects

Substances

  • Anti-Obesity Agents
  • Orlistat
  • Phentermine